Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

被引：0
|
作者：
Rizzo, Alessandro [1 ]
Frega, Giorgio [2 ]
Ricci, Angela Dalia [1 ]
Palloni, Andrea [1 ]
Tavolari, Simona [3 ]
Brandi, Giovanni [2 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med DIMES, Bologna, Italy
[2] Policlin S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[3] Univ Bologna, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
    Yu, Xinlin
    Wei, Chun
    Cui, Ran
    Jiang, Ou
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2023, 16 (11): : 321 - 331
  • [22] Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials
    Shao, Yu-Yun
    Shau, Wen-Yi
    Chan, Soa-Yu
    Lu, Li-Chun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    ONCOLOGY, 2015, 88 (06) : 345 - 352
  • [23] Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
    Petrelli, Fausto
    Ferrara, Roberto
    Signorelli, Diego
    Ghidini, Antonio
    Proto, Claudia
    Roudi, Raheleh
    Sabet, Mehrdad N.
    Facelli, Sara
    Garassino, Marina C.
    Luciani, Andrea
    Roviello, Giandomenico
    IMMUNOTHERAPY, 2021, 13 (07) : 621 - 632
  • [24] Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis
    Zhang, Yangfeng
    Li, Chunhui
    Du, Kunpeng
    Pengkhun, Nov
    Huang, Zijian
    Gong, Min
    Li, Yanyang
    Liu, Xiang
    Li, Lilin
    Wang, Duanyu
    Wang, Changqian
    Chen, Fengsheng
    Li, Jiqiang
    IMMUNOTHERAPY, 2023, 15 (10) : 737 - 750
  • [25] Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials
    Wang, Shuangyue
    Huang, Xiaojie
    Li, Rong
    Zhou, Ziyan
    Kang, Min
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2024, 281 (10) : 5111 - 5118
  • [26] The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Li, Dailong
    Zhang, Chunzhen
    Yang, Kui
    Ma, Zhiwei
    Ma, Lili
    Cheng, Chunlai
    Xu, Lu
    Wan, Sha
    MEDICINE, 2024, 103 (03) : E36865
  • [27] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
    Guo, Tian-Kang
    Hao, Xiang-Yong
    Ma, Bin
    Yang, Ke-Hu
    Li, Yi-Ping
    Li, Hong-Ling
    Gu, Yuan-Hui
    Cai, Hui
    Liu, Ya-Li
    Li, Yuan
    Zhan, Wei-Peng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (12) : 1685 - 1692
  • [28] Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
    Tian-Kang Guo
    Xiang-Yong Hao
    Bin Ma
    Ke-Hu Yang
    Yi-Ping Li
    Hong-Ling Li
    Yuan-Hui Gu
    Hui Cai
    Ya-Li Liu
    Yuan Li
    Wei-Peng Zhan
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1685 - 1692
  • [29] Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma
    Alsina, Maria
    Fleitas-Kanonnikoff, Tania
    MED, 2024, 5 (09): : 1038 - 1040
  • [30] Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Tun, Aung Myint
    Thein, Kyaw Zin
    LinThein, Wai
    Guevara, Elizabeth
    FUTURE SCIENCE OA, 2019, 5 (09):
12345